The IMI PROTECT project: purpose, organizational structure, and procedures.

Area of Science:

• Pharmacoepidemiology
• Pharmacovigilance
• Drug Safety Research

Background:

• Current pharmacoepidemiology and pharmacovigilance methods have limitations.
• The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT) initiative was a collaborative European project (2009-2015).
• It was part of the Innovative Medicines Initiative, involving 35 partners from academia, regulatory bodies, and industry.

Purpose of the Study:

• To address limitations in current pharmacoepidemiology and pharmacovigilance.
• To investigate how variations in study design, methodology, and data sources impact results in observational drug safety studies.
• To improve the reliability and consistency of drug safety research.

Main Methods:

• Applied different study designs and analytical methodologies to six drug-adverse event pairs.
• Utilized multiple electronic healthcare databases and registries for analysis.
• Focused on understanding the extent of result discrepancies caused by methodological differences.

Main Results:

• The project evaluated the impact of study design, methodology, and data source choices on observational drug safety study outcomes.
• It identified factors contributing to discrepant results in drug safety research.
• The findings provide insights into optimizing observational study methodologies.

Conclusions:

• The PROTECT initiative successfully examined sources of discrepancy in drug safety research.
• Understanding these variations is crucial for enhancing the accuracy and trustworthiness of pharmacoepidemiological studies.
• The project's organizational structure and procedures offer a model for managing complex, multi-partner research initiatives.